Английская Википедия:Ibodutant

Материал из Онлайн справочника
Версия от 23:16, 24 марта 2024; EducationBot (обсуждение | вклад) (Новая страница: «{{Английская Википедия/Панель перехода}} {{Short description|Chemical compound}} {{Drugbox | Verifiedfields = changed | verifiedrevid = 444434892 | IUPAC_name = ''N''α-[(1-<nowiki/>{[(6-methyl-1-benzothien-2-yl)carbonyl]amino}cyclopentyl)carbonyl]-''N''-<nowiki/>{[1-(tetrahydro-2''H''-pyran-4-ylmethyl)piperidin-4-yl]methyl}-<small>D</small>-phenylalaninamide | image = Ibodutant_structure.svg | width = 150px <!--Clinical dat...»)
(разн.) ← Предыдущая версия | Текущая версия (разн.) | Следующая версия → (разн.)
Перейти к навигацииПерейти к поиску

Шаблон:Short description Шаблон:Drugbox

Ibodutant was a candidate drug for irritable bowel syndrome diarrhea, developed by The Menarini Group. Шаблон:As of, it underwent a multicentre double blind efficacy clinical study. Ibodutant selectively blocks the tachykinin receptor NK2, with blockade practically complete in nanomolar concentrations. A phase 2 trial in Europe (the IRIS-2 trial) completed in May 2012 with positive results. A 52-week phase 3 study was terminated as of 2015 because of low response and negative results of study NAK-06.[1]

See also

References

Шаблон:Reflist

Further reading

Шаблон:Refbegin

Шаблон:Refend

Шаблон:Neurokinin receptor modulators


Шаблон:Nervous-system-drug-stub